Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health
April 02, 2019 10:02 ET | Admera Health, LLC
NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at...
Synergy CHC Corp. Announces Fiscal 2018 Year End Results
March 29, 2019 17:30 ET | Synergy CHC Corp
Westbrook, Maine, March 29, 2019 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (OTCQB: SNYR) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the fiscal...
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting
March 26, 2019 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...
Entrepix Receives Mu
Entrepix Receives Multiple Orders for New DSS-200 Synergy Cleaning Systems
July 09, 2018 08:00 ET | Entrepix, Inc.
PHOENIX, July 09, 2018 (GLOBE NEWSWIRE) -- Entrepix Inc., a leading provider of wafer cleaning and chemical mechanical planarization (CMP) equipment and process services, today announced it has...
Metaswitch Recognized as Global Market Leader in Virtualized SBC
May 09, 2016 09:00 ET | Metaswitch Networks
LONDON, UNITED KINGDOM--(Marketwired - May 09, 2016) -  Network software provider Metaswitch Networks® is the market leader in global shipments of virtualized session border controllers...
Rhizen Pharmaceutica
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
November 18, 2014 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple Myeloma. ...
ShoreTel Surpasses 10,000 Enterprise Customers
July 27, 2009 08:00 ET | ShoreTel
SUNNYVALE, CA--(Marketwire - July 27, 2009) - ShoreTel® (NASDAQ: SHOR), the leading provider of brilliantly simple IP phone systems with fully integrated Unified Communications (UC), today...